ATAXION
Ataxion is a discovery-stage biopharmaceutical company developing novel therapies for rare, debilitating, and underserved neurologic diseases. Located in Cambridge, Massachusetts, Ataxion was founded in April 2013 out of the Atlas Venture seed program by Dr. Josh Resnick and Atlas Venture Development Corporation Managing Director and Ataxion Board Member David Grayzel, MD.
ATAXION
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
2013-04-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.ataxiontherapeutics.com
Total Employee:
11+
Status:
Closed
Contact:
(617)588-2644
Total Funding:
17 M USD
Similar Organizations
Anebulo Pharmaceuticals
Anebulo is a biotech company developing novel solutions for people suffering from cannabinoid overdose and substance addiction.
Apic Bio
Apic Bio is a gene therapy company that develops treatment options for rare, undertreated neurological and liver diseases.
Aviceda Therapeutics
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases.
Cortene
Cortene is a clinical-stage biopharmaceutical company focused on developing treatments for chronic fatigue syndrome and other diseases.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Glycostem Therapeutics
Glycostem is a clinical stage biotech company developing off-the shelf allogeneic cellular immunotherapy using Natural Killer (NK) cells.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Tetris Pharma
UK based niche speciality pharmaceutical company building a European platform to market a range of prescription products
Current Advisors List
Current Employees Featured
Founder
Investors List
Biogen
Biogen investment in Series A - Ataxion
Atlas Venture
Atlas Venture investment in Series A - Ataxion
Official Site Inspections
http://www.ataxiontherapeutics.com
Unable to get host informations!!!
More informations about "Ataxion"
Ataxion Company Profile 2024: Valuation, Investors, Acquisition
Ataxion General Information Description. Developer of novel small-molecule therapeutics designed for neurological diseases. The company's novel small-molecule therapeutics offers a …See details»
Ataxion - Crunchbase Company Profile & Funding
Organization. Ataxion . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Ataxion is a discovery-stage biopharmaceutical …See details»
Ataxion - Products, Competitors, Financials, Employees, …
Clal Biotech co Luk buys Ataxion Therapeutics. Mar 7, 2017. Globes English - Clal Biotech co Luk buys Ataxion Therapeutics. Apr 9, 2014. Pushing Forward With Collaborative R&D Models In …See details»
Ataxion Inc - Company Profile and News - Bloomberg Markets
Company profile page for Ataxion Inc including stock price, company news, executives, board members, and contact informationSee details»
Ataxion, Inc.: Drug pipelines, Patents, Clinical trials - Synapse
Jun 28, 2023 Explore Ataxion, Inc. with its drug pipeline, therapeutic area, technology platform, 1 news.See details»
Ataxion Company Profile - Office Locations, Competitors ... - Craft
See insights on Ataxion including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Cadent Therapeutics acquires Ataxion - 2017-03-07 - Crunchbase
Mar 7, 2017 Disposition of Acquired Organization Subsidiary; Recent News. Edit Recent News Section. News • Mar 8, 2017. Clal Biotech co Luk buys Ataxion Therapeutics . Unlock even …See details»
Saniona AB: Saniona announces a merger of its spinout
PRESS RELEASE. March 6, 2017. Saniona, a leading biotech company within ion-channel research, today announces that its spinout company Ataxion has engaged into a merger with …See details»
M&As this week: Ataxion, Kasten, Heat Biologics
Mar 9, 2017 Ataxion, a spinout company of biotechnology firm Saniona, is set to merge with Luc Therapeutics.. The merged company will continue to operate as Luc Therapeutics, in which …See details»
Ataxion - VentureRadar
Molecular Imaging USA Privately Held Molecular Imaging, Inc. is a specialty contract research organization (CRO) located in Ann Arbor, Michigan. Molecular Imaging employs a wide array …See details»
Clal Biotech co Luk buys Ataxion Therapeutics - Globes
The biomed investment company also announced Ofer Gonen's permanent appointment as CEO. Biomed investment company Clal Biotechnology Industries Ltd. (TASE: CBI) today announced …See details»
Ataxion - Company Profile - Tracxn
Nov 4, 2024 Ataxion - Discovering and developing small molecule therapeutics targeting ion channel with central nervous system.. This company is not active anymore. Raised a total …See details»
BioCentury - Ataxion, Luc Therapeutics deal
Mar 17, 2017 Ataxion will merge with Luc; the newco will retain Luc's name and focus on precision medicine for neurological and psychiatric diseases. Its pipeline includes programs to …See details»
Ataxion Announces $17M Series A Financing from Atlas ... - Fierce …
Mar 17, 2014 Ataxion Announces $17M Series A Financing from Atlas Venture and Biogen Idec CAMBRIDGE, MASSACHUSETTS, March 17, 2014 Ataxion, Inc, a discovery-stage …See details»
Ataxion Announces $17M Series A Financing from Atlas
Mar 17, 2014 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ataxion, Inc, a discovery-stage biopharmaceutical company developing novel therapies for rare, debilitating, and underserved …See details»
Biogen, Atlas Venture collaborate on treatment for ataxia
Mar 17, 2014 Biogen and Atlas Venture are investing $17 million in Ataxion, a life sciences industry startup to develop treatments for inherited forms of ataxia, an orphan disease.See details»
Alexion, AstraZeneca Rare Disease to Acquire LogicBio® …
Oct 3, 2022 LogicBio acquisition to build on current collaborations and advancements in genomic medicine. Alexion, AstraZeneca Rare Disease, today announced that it has entered a …See details»
AmyriAD – MEMORIES ARE WORTH FIGHTING FOR
AMYRIAD is committed to modernizing current techniques for staging AD severity and assessing the impact of drug treatments. We are partnering with experts in digital technologies to …See details»
Alexion
The World Health Organization estimates that one out of 15 people worldwide could be affected by a rare disease. For more information: https://bit.ly/2EhEfWG Generalized myasthenia gravis …See details»